Author:
Polumuri Swamy Kumar,Haile Lydia A.,Ireland Derek D. C.,Verthelyi Daniela
Publisher
Springer Science and Business Media LLC
Reference73 articles.
1. Rosenberg, A. S. & Worobec, A. Immunogenicity Concerns of Therapeutic Protein Products. Part 1 Considering the Consequences of the Immune Response to a Protein. BioPharm. Int, 22–26 (2005).
2. Boven, K. et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 20(Suppl 3), iii33–40,
https://doi.org/10.1093/ndt/gfh1072
(2005).
3. Schellekens, H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clinical Therapeutics 24, 1720–1740 (2002).
4. Ahmadi, M. et al. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res 32, 1383–1394,
https://doi.org/10.1007/s11095-014-1541-x
(2015).
5. Ryff, J. C. Clinical investigation of the immunogenicity of interferon-alpha 2a. J Interferon Cytokine Res 17(Suppl 1), S29–33 (1997).
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献